Has Chad Tang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $183,053 in general payments to Chad Tang, MD across 110 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Chad Tang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Chad Tang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Chad Tang, MD

Radiation Oncology · Houston, TXNPI 1376899419

Payments from drug & device makers

What this record shows

This record is dominated by grants: $151,500 of the $183,053 with a category attached, or 82.8%. E.r. Squibb & Sons, L.L.C. accounts for 81.9% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $70,893 and has fallen 94.0% since, to $4,226 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$183,053in general payments, 2019–2025

Across 110 payments — averaging $1664.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$150K
Boston Scientific$9K
Siemens Medical Solutions USA, Inc.$9K
Bayer$4K
Elekta, Inc.$4K
Telix Pharmaceuticals$3K
plus $5K from 15 others

$7,549,307in research payments, 2019–2025

Across 8 payments — averaging $943,663 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$7.1M
Varian Medical Systems, Inc.$356K
Myriad Genetic Laboratories, Inc.$71K

What the payments were for

Consulting fees$18,81410%
Speaking & faculty fees$1,9591%
Grants$151,50083%
Travel & lodging$3,1232%
Food & beverage$7,6574%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	3	$150,000
Boston Scientific	34	$9,108
Siemens Medical Solutions USA, Inc.	11	$8,524
Bayer	8	$4,055
Elekta, Inc.	7	$3,602
Telix Pharmaceuticals	11	$2,664
Molli Surgical (US) Inc	3	$1,888
AstraZeneca	10	$781
Raysearch Laboratories AB (publ)	1	$485
Pfizer	5	$392
Reflexion Medical, Inc.	2	$238
Exelixis Inc.	2	$232
Visionrt, Inc.	1	$221
Bioprotect Medical, Inc.	2	$172
Johnson & Johnson	1	$150
AVEO Pharmaceuticals, Inc.	1	$144
Novartis	2	$131
Sumitomo Pharma America, Inc.	1	$116
Blue Earth Diagnostics	2	$55
Ion Beam Applications S.A.	1	$51
Shockwave Medical, Inc	2	$43

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SpaceOAR System$5,689
Nubeqa$3,838
ILLUCCIX$1,954
ELEKTA MEDICAL LINEAR ACCELERATOR$1,633
ELEKTA UNITY$1,459
SpaceOAR VUE System - 10mL$1,458
IMFINZI$555
Cabometyx$232
REFLEXION MEDICAL RADIOTHERAPY SYSTEM$213
Erleada$150
Balversa$150
FOTIVDA$144
Xofigo$132
GENERAL BPH$125
GENERAL ONCOLOGY$120
ORGOVYX$116
GENERAL - THERAPIES$107
PADCEV$100

How this compares

$183,053 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas →

Medicare billing

Part B allowed, 2024

$245,213

Medicare patients

265

Services billed

2,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	11	$213

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Houston

James WelshHouston$421K
Stephen ChunHouston$344K
Phuoc TranHouston$177K
Steven LinHouston$105K
Benjamin SchrankHouston$100K
Abhilasha PatelHouston$76K
Joe ChangHouston$50K
Daniel GomezHouston$47K
David RosenthalHouston$40K
Andrew FarachHouston$36K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →